Vion Pharmaceuticals Enters Into Agreement With HOVON To Conduct A Phase III Clinical Trial Of Cloretazine(R) VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).
Source: www.medicalnewstoday.comFDA Approval, Oversight Of Mifeprex 'Consistent' With Other Drugs, GAO Report Says FDA's approval process and postmarket oversight of Danco Laboratories' medication abortion drug Mifeprex, also known as RU-486, were "consisten[t]" with how the agency handles other
drugs with restricted distribution, according to a Government Accountability Office report released Tuesday,
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
